BioSpace News Archive

Cleveland Clinic, Mayo Clinic, St. Jude Children’s Research Hospital Claim Top Spots

Feb. 19, 2020 13:00 UTC BERKELEY, Calif. & RICHMOND, Calif.--( BUSINESS WIRE )-- Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic eng

Feb. 19, 2020 13:00 UTC Industry veteran to helm newly created position as H3 advances oncology pipeline CAMBRIDGE, Mass.--( BUSINESS WIRE )-- H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the appointment of Antonio Gualberto, MD, PhD, to the position of Chief Medical Officer (CMO). Dr. Gualberto will oversee global clinical research & development for the H3 pipeline of clinical sta

Feb. 19, 2020 13:00 UTC Partnership augments caresyntax’s digital ecosystem in surgery, accelerates solution delivery and increases integration capacity. BOSTON--( BUSINESS WIRE )-- caresyntax, a pioneer in surgical automation, quality analytics and AI software and technologies, today announced the launch of a new partnership with Diversified, an industry leading technology solutions integrator. The partnership will enable caresyntax to accelerate the development and deploy

BERKELEY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 9 th Annual SVB Leerink Global Healthcare Conference in New York, New York on Wednesday, February 26, 2020 at 9:00 am ET. To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro’s website at

Feb. 19, 2020 13:00 UTC Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance CULVER CITY, Calif.--( BUSINESS WIRE )-- NantOmics, LLC , the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed stu

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 prior to the open of the market.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company successfully completed 100 patient cases with its PURE EP(tm) System.

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board member with experience in pharma, biotech, and venture capital, has been elected as a member of the Delcath Board of Directors effective February 14, 2020.

NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection platform to develop targeted anticancer immunotherapies, has closed a $45 million Series C financing.